PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
JAK Inhibitors in the Management of Dermatologic Disorders: Clinical Implications of the Latest Safety Findings
Visit https://www.peervoice.com/PDW860 to view the entire programme with slides. After completing “JAK Inhibitors in the Management of Dermatologic Disorders: Clinical Implications of the Latest Safety Findings”, participants will be able to: Describe the patient demographics in the safety studies for Janus kinase (JAK) inhibitors; Summarise key safety data for approved and emerging JAK inhibitors in patients with atopic dermatitis (AD) or alopecia areata (AA); Use clinical and patient characteristics in the context of AD or AA to determine appropriate benefit and risk profiles when considering the use of a JAK inhibitor.